# US 2021/0260082 A1 · Phosphinic amide prodrugs of tenofovir

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260082 A1
- Document ID: US20210260082A1
- Status: Published application
- Kind: A1
- Application number: 17/260,619
- Filed: 2019-07-15
- Published: 2021-08-26
- Earliest claimed: 2018-07-19
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Manuel De Lera Ruiz; Izzat Raheem; Michael T. Rudd
- Web page: https://patentgrep.com/patent/US20210260082A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/52: Purines, e.g. adenine
- A61K 31/536: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- C07F 9/65616: {containing the ring system [IMAGE cpc-sch-C07F-1006.gif] having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is (a) —C1-4alkyl, (b) —C1-4alkyl substituted with —OH, —SH, —SCH3, —NH2, —NH—C(═NH)—NH2, (c) —CH2-phenyl, (d) —CH2-phenol, (e) —(CH2)1-2—COOH, (f) —(CH2)1-2—CONH2, (g) —CH2-1H-indole, (h) —CH2-imidazole, (i) aryl or (j) heteroaryl;
—R2 is (a) —C1-4alkyl, (b) —C1-4alkyl substituted with —OH, —SH, —SCH3, —NH2, —NH—C(═NH)—NH2, (c) —CH2-phenyl, (d) —CH2-phenol, (e) —(CH2)1-2—COOH, (f) —(CH2)1-2—CONH2, (g) —CH2-1H-indole, (h) —CH2-imidazole, (i) aryl or (j) heteroaryl;
or R1 and R2 are joined together with the carbon to which they are both attached to form —C3-6cycloalkyl or a 4 to 6-membered heterocyclic ring;
R3 is —CN, —CF3, phenyl, heteroaryl, —C(O)OR5b, —C(O)—N(R6a)(R6b), —S(O)2R5b or —S(O)2—N(R6a)(R6b) wherein each of phenyl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected at each occurrence from R10;
R4 is —H, —CN, —CF3, phenyl, heteroaryl, —C(O)OR5c or —C(O)—N(R6c)(R6d), —S(O)2R5c or —S(O)2—N(R6c)(R6d) wherein each of phenyl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected at each occurrence from R10;
R5a, R5b and R5c are each independently:
(a) —C1-10alkyl unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —CN, —CF3, —NR7aR7b, —OR8, —SH, —C3-6cycloalkyl or spiro-C3-6cycloalkyl,
(b) —CH2-phenyl unsubstituted or substituted with one to three substituents, wherein each substituent is independently selected at each occurrence from R10,
(c) —C3-8 cycloalkyl unsubstituted or substituted with one to three substituents, wherein each substituent is independently selected at each occurrence from R10,
(d) aryl unsubstituted or substituted with one to three substituents, wherein each substituent is independently selected at each occurrence from R10,
(e) —C1-5alkyl-X—C1-5alkyl wherein X is O, S or NH,
(f) heteroaryl unsubstituted or substituted with one to three substituents, wherein each substituent is independently selected at each occurrence from R10, or
(g) a heterocyclic ring unsubstituted or substituted with one to three substituents, wherein each substituent is independently selected at each occurrence from R10;
R6a, R6b, R6c and R6d are each independently —H, —C1-3alkyl or —C3-6cycloalkyl;
R7a and R7b are each independently —H, —C1-3alkyl or —C3-6cycloalkyl;
R8 is —H or —C3-6cycloalkyl; and
R9 is —H, —C1-3alkyl or —C3-6cycloalkyl; and
R10 is fluoro, chloro, bromo, —CN, —CF3, —NR7aR7b, —OR9, —SH or —C1-3alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both the same and are selected from methyl, ethyl, propyl or i-propyl.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both methyl.

### Claim 4 (depends on 2)

The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R3 is
(a) —C1-8alkyl, —CH2CH2OH, —CH2CH2CH2OH, —CH2CH2SH, —CH2CH2CH2SH, —CH2CH2NH2, —CH2CH2CH2NH2, —CH2CF2CH3 or —CH2CH2CF3;
(b) —CH2-phenyl, unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8a, —SH, —NR6R7 or —C1-3alkyl,
(c) —C3-6cycloalkyl, unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8a, —SH, —NR6R7 or —C1-3alkyl,
(d) phenyl or naphthyl, each unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8a, —SH, —NR6R7 or —C1-3 alkyl,
(e) —CH2CH2OCH3, —CH2CH2CH2OCH3, —CH2CH2SCH3, —CH2CH2CH2SCH3, —CH2CH2NHCH3, —CH2CH2CH2NHCH3,
(f) pyridyl, unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8a, —SH, —NR6R7 or —C1-3alkyl, or
(g) piperidinyl, pyrrolidinyl, tetrahydrofuranyl, or tetrahydropyranyl, each unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8a, —SH, —NR6R7 or —C1-3alkyl.

### Claim 5 (depends on 4)

The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R4 is
(a) —C1-8alkyl, —CH2CH2OH, —CH2CH2CH2OH, —CH2CH2SH, —CH2CH2CH2SH, —CH2CH2NH2, —CH2CH2CH2NH2, —CH2CF2CH3 or —CH2CH2CF3;
(b) —CH2-phenyl, unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8b, —SH, —NR9R10 or —C1-3alkyl,
(c) —C3-6cycloalkyl, unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8b, —SH, —NR9R10 or —C1-3alkyl,
(d) phenyl or naphthyl, each unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8b, —SH, —NR9R10 or —C1-3alkyl,
(e) —CH2CH2OCH3, —CH2CH2CH2OCH3, —CH2CH2SCH3, —CH2CH2CH2SCH3, —CH2CH2NHCH3, —CH2CH2CH2NHCH3,
(f) pyridyl, unsubstituted or substituted with one to three substituents independently, wherein each substituent is independently from fluoro, chloro, bromo, —OR8b, —SH, —NR9R10 or —C1-3alkyl, or
(g) piperidinyl, pyrrolidinyl, tetrahydrofuranyl, or tetrahydropyranyl, each unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8b, —SH, —NR9R10 or —C1-3 alkyl.

### Claim 6 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R3 is:
(a) —C1-8alkyl, —CH2CH2OH, —CH2CH2CH2OH, —CH2CH2SH, —CH2CH2CH2SH, —CH2CH2NH2, —CH2CH2CH2NH2, —CH2CF2CH3 or —CH2CH2CF3;
(b) —CH2-phenyl, unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8a, —SH, —NR6R7 or —C1-3alkyl, or
(c) —C3-6cycloalkyl, unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8a, —SH, —NR6R7 or —C1-3 alkyl.
and R4 is:
(a) —C1-8alkyl, —CH2CH2OH, —CH2CH2CH2OH, —CH2CH2SH, —CH2CH2CH2SH, —CH2CH2NH2, —CH2CH2CH2NH2, —CH2CF2CH3 or —CH2CH2CF3;
(b) —CH2-phenyl, unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8b, —SH, —NR9R10 or —C1-3alkyl, or
(c) —C3-6cycloalkyl, unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —OR8b, —SH, —NR9R10 or —C1-3alkyl.

### Claim 7 (depends on 2)

The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein:
R3 is —CN, unsubstituted or substituted phenyl, —C(O)OR5b or —C(O)—N(R6a)(R6b); and
R4 is —H, —CN, unsubstituted or substituted phenyl, —C(O)OR5c or —C(O)—N(R6c)(R6d).

### Claim 8 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein:
R5a, R5b and Rsc are each independently —C1-10alkyl unsubstituted or substituted with one to three substituents, wherein each substituent is independently selected from fluoro, chloro, bromo, —CN, —CF3, —NR7aR7b, —OR8a, —SH, —C3-6cycloalkyl or spiro-C3-6cycloalkyl; and
R6a, R6b, R6c and R6d are each —C1-6alkyl.

### Claim 9 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein R5a, R5b and R5c are each —C1-6alkyl.

### Claim 10 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:
R1 and R2 are both methyl,
R3 is —CN, phenyl, —C(O)OR5b or —C(O)—N(R6a)(R6b);
R4 is —H, —CN, phenyl, —C(O)OR5c or —C(O)—N(R6c)(R6d);
each of R5a, R5b and R5c is —C1-6alkyl; and
each of R6a, R6b, R6c and R6d is —C1-6alkyl.

### Claim 11 (depends on 1)

The compound of claim 1 that is:
Propyl 2-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(1-cyano-2-isopropoxy-2-oxoethyl)phosphorylamino)-2-methylpropanoate;
Diisopropyl 2-((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((2-methyl-1-oxo-1-propoxypropan-2-yl)amino)phosphoryl)malonate;
Diisopropyl 2-((R)-((((S)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((2-methyl-1-oxo-1-propoxypropan-2-yl)amino)phosphoryl)malonate;
Propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(2-isopropoxy-2-oxoethyl)phosphoryl)amino)-2-methylpropanoate;
Propyl 2-(((R)-((((S)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(2-isopropoxy-2-oxoethyl)phosphoryl)amino)-2-methylpropanoate;
Propyl 2-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(cyanomethyl)phosphorylamino)-2-methylpropanoate;
Propyl 2-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(2-isopropoxy-2-oxo-1-phenylethyl)phosphorylamino)-2-methylpropanoate;
Propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(dicyanomethyl)phosphoryl)amino)-2-methylpropanoate;
Propyl 2-(((R)-((((S)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(dicyanomethyl)phosphoryl)amino)-2-methylpropanoate;
Propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(2-(diethylamino)-2-oxoethyl)phosphoryl)amino)-2-methylpropanoate;
propyl 2-(((R)-((((S)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(2-(diethylamino)-2-oxoethyl)phosphoryl)amino)-2-methylpropanoate;
Propyl 2-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(2-tert-butoxy-2-oxoethyl)phosphorylamino)-2-methylpropanoate;
Propyl 2-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(benzyl)phosphorylamino)-2-methylpropanoate;
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising an effective amount of the compound according to any one of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12 further comprising an effective amount of one or more additional HIV antiviral agents selected from HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors and HIV entry inhibitors.

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12 further comprising an effective amount of one or more additional HIV antiviral agents selected from: abacavir, abacavir sulfate, abacavir+lamivudine, abacavir+lamivudine+zidovudine, amprenavir, atazanavir, atazanavir sulfate, AZT, capravirine, darunavir, dideoxycytidine, dideoxyinosine, delavirdine, delavirdine mesylate, dolutegravir, doravirine, efavirenz, 4′-ethynyl-2-fluoro-2′-deoxyadenosine, elvitegravir, emtricitabine, emivirine, enfuvirtide, etravirine, fosamprenavir calcium, indinavir, indinavir sulfate, lamivudine, lamivudine+zidovudine, lopinavir, lopinavir+ritonavir, maraviroc, nelfinavir, nelfinavir mesylate, nevirapine, PPL-100, raltegravir, rilpivirine, ritonavir, saquinavir, saquinavir mesylate, stavudine, tipranavir, or vicriviroc.

### Claim 15 (depends on 1)

A method for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15 further comprising administering to the subject an effective amount of one or more additional HIV antiviral agents selected from HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors and HIV entry inhibitors.

### Claim 17 (depends on 15)

The method of claim 15 further comprising administering to the subject an effective amount of one or more additional HIV antiviral agents selected from: abacavir, abacavir sulfate, abacavir+lamivudine, abacavir+lamivudine+zidovudine, amprenavir, atazanavir, atazanavir sulfate, AZT, capravirine, darunavir, dideoxycytidine, dideoxyinosine, delavirdine, delavirdine mesylate, dolutegravir, doravirine, efavirenz, 4′-ethynyl-2-fluoro-2′-deoxyadenosine, elvitegravir, emtricitabine, emivirine, enfuvirtide, etravirine, fosamprenavir calcium, indinavir, indinavir sulfate, lamivudine, lamivudine+zidovudine, lopinavir, lopinavir+ritonavir, maraviroc, nelfinavir, nelfinavir mesylate, nevirapine, PPL-100, raltegravir, rilpivirine, ritonavir, saquinavir, saquinavir mesylate, stavudine, tipranavir, or vicriviroc.

### Claim 18 (depends on 15)

The method of claim 15 wherein the subject is human.

### Claim at position 19

19-21. (canceled)
